Developing the best MATCH for patients through plug & play assembly of novel multispecific biotherapeutics.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
March 30, 2020

Numab Therapeutics Expands Immuno-Oncology Research Alliance with Ono Pharmaceutical Co., Ltd.

Numab announced today an expansion of its relationship with Ono…

Numab announced today an expansion of its relationship with Ono Pharmaceutical Co., Ltd. by executing another research and option agreement to discover and develop a multi-specific antibody drug candidate for the treatment of various cancers. Similar to their earlier collaboration initiated in March 2017, under this new agreement, Ono has obtained an option to acquire from Numab exclusive rights to develop and commercialize an immuno-oncology drug candidate that will leverage Numab’s platform technology in order to actualize one of Ono’s novel therapeutic approaches. In exchange, Ono will pay to Numab up to CHF 260 million in upfront and milestone payments plus tiered single to double-digit royalties on sales.
March 09, 2020

Numab Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology

Numab Therapeutics AG announced today the closing of its Series B…

Numab Therapeutics AG announced today the closing of its Series B financing round at a total volume of CHF 22M (approximately USD 22.6M). New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella. Existing shareholders that participated in Numab’s Series A round also contributed to today’s financing. With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic. The company also plans to initiate a clinical trial for its lead oncology program ND021 during the course of 2020.
December 12, 2019

Numab and 3SBio Group form partnership to develop novel multi-specific antibodies in IO

Numab Therapeutics AG today announced a partnership with 3SBio’s…

Numab Therapeutics AG today announced a partnership with 3SBio’s subsidiary Sunshine Guojian Pharmaceutical focusing on the development and commercialization of a portfolio of novel multi-specific cancer antibodies. As part of the alliance, Sunshine Guojian has invested CHF15M (approximately USD 15.2M) in Numab’s series B financing.
More News
Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept